Stryker Corp. SYK

NYSE; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0000310764

B

second fifth of 370 graded peers in healthcare

rank 119 of 370; percentile 32.0; sampling error 2.5 points; lower is stronger

A B C D E

B, the elk



Scoreboard


Profitability	B percentile 37.2
Solvency	C percentile 47.6
Growth and financing	C percentile 43.2
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $47.8B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	10 of 14
Graded from	filings received through Feb 11, 2026 268 days before the rescan; latest periodic filing 10-Q received Oct 30, 2026
Last close	$335.05 2026-11-05; market equity $127.6B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 11, 2026

Stryker Corporation (Stryker or the Company) is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million Stryker was incorporated in Michigan in 1946 as the successor company to a business founded in 1941 by Dr. Homer H. Stryker, a prominent orthopaedic surgeon and inventor of several medical products.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 37.2						
Gross profitability	33.6%	32.3%		42.3	365	2025-12-31
Return on invested capital	not computable	9.3%				


latest aligned inputs end 2011-12-31; latest annual assets end 2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(4.0%)	(6.6%)	66.0	802	2025-12-31
Gross margin stability, five years	0.5 pts	2.8 pts	3.3	242	2025-12-31
Solvency, sleeve percentile 47.6					
Twelve-month failure probability	not computable	0.07%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	3.96	(0.37)	21.8	747	2025-12-31
Net debt to EBITDA	not computable	1.82x			
latest aligned inputs end 2011-12-31; latest annual assets end 2025-12-31					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	1.89x	2.94x	73.3	828	2025-12-31
Growth and financing, sleeve percentile 43.2					
Revenue growth, three-year compound	10.8%	10.0%	48.7	412	2025-12-31
Free cash flow growth, three-year compound	28.1%	10.9%	35.8	96	2025-12-31
Reinvestment rate	(30.7%)	37.1%	82.7	105	2025-12-31
Asset growth, three years	9.1%	2.2%	32.9	696	2025-12-31
Net share issuance, one year	0.3%	2.5%	15.7	630	2026-01-31

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
114	Tandem Diabetes Care Inc. (TNDM)	30.6	B	
115	BioNexus Gene Lab Corp. (BGLC)	30.9	B	dilution, late filer
116	Arcutis Biotherapeutics, Inc. (ARQT)	31.2	B	
117	Insmed Inc. (INSM)	31.4	B	
118	Biocryst Pharmaceuticals Inc. (BCRX)	31.7	B	fortress balance sheet
119	Stryker Corp. (SYK)	32.0	B	
120	Verastem, Inc. (VSTM)	32.2	B	dilution, fortress balance sheet
121	Usana Health Sciences Inc. (USNA)	32.5	B	
122	Eton Pharmaceuticals, Inc. (ETON)	32.8	B	
123	Collegium Pharmaceutical, Inc. (COLL)	33.1	B	fortress balance sheet
124	Koru Medical Systems, Inc. (KRMD)	33.3	B	fortress balance sheet

What the price implies

at the 2026-11-05 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(22.1%)	(2.1%)	36
Distance from 52-week high	(13.5%)	(30.4%)	70
EBIT to enterprise value	3.9%	(1.5%)	71
Free cash flow yield	3.4%	(1.0%)	71
Book value to price	0.18	0.29	37
Sales to price	0.20	0.30	39

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Composite equity issuance, five years	(4.5%)	21.4%	20
Relative strength against the sector, log excess return	(0.42)	(0.19)	36

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 6 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$3.3B
Operating cash flow, four quarters	$5.4B
Months of runway	not finite
Days since last periodic filing	7 (10-Q received Oct 30, 2026)
Median daily dollar volume, 63 sessions	$744.2M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$16.1B	2025-12-31	2026-02-11	10-K	26-000010
2	assets	us-gaap:Assets	$47.8B	2025-12-31	2026-02-11	10-K	26-000010
3	operating income	us-gaap:OperatingIncomeLoss	$1.7B	2011-12-31	2014-02-13	10-K	14-000021
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$1.7B	2011-12-31	2014-02-13	10-K	14-000021
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$341.0M	2011-12-31	2014-02-13	10-K	14-000021
6	total debt	us-gaap:LongTermDebt	$1.8B	2011-12-31	2012-02-13	10-K	12-000031
7	book equity	us-gaap:StockholdersEquity	$7.7B	2011-12-31	2015-02-12	10-K	15-000022
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$905.0M	2011-12-31	2015-02-12	10-K	15-000022
9	total debt	us-gaap:LongTermDebt	$1.0B	2010-12-31	2012-02-13	10-K	12-000031
10	book equity	us-gaap:StockholdersEquity	$7.2B	2010-12-31	2014-02-13	10-K	14-000021
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$1.8B	2010-12-31	2014-02-13	10-K	14-000021
12	net income	us-gaap:NetIncomeLoss	$3.2B	2025-12-31	2026-02-11	10-K	26-000010
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$5.0B	2025-12-31	2026-02-11	10-K	26-000010
14	assets	us-gaap:Assets	$43.0B	2024-12-31	2026-02-11	10-K	26-000010
15	revenue	us-gaap:Revenues	$25.1B	2025-12-31	2026-02-11	10-K	26-000010
16	gross profit	us-gaap:GrossProfit	$14.4B	2024-12-31	2026-02-11	10-K	26-000010
17	revenue	us-gaap:Revenues	$22.6B	2024-12-31	2026-02-11	10-K	26-000010
18	gross profit	us-gaap:GrossProfit	$13.1B	2023-12-31	2026-02-11	10-K	26-000010
19	revenue	us-gaap:Revenues	$20.5B	2023-12-31	2026-02-11	10-K	26-000010
20	gross profit	us-gaap:GrossProfit	$11.6B	2022-12-31	2025-02-12	10-K	25-000023
21	revenue	us-gaap:Revenues	$18.4B	2022-12-31	2025-02-12	10-K	25-000023
22	gross profit	us-gaap:GrossProfit	$11.0B	2021-12-31	2024-02-14	10-K	24-000024
23	revenue	us-gaap:Revenues	$17.1B	2021-12-31	2024-02-14	10-K	24-000024
24	current assets	us-gaap:AssetsCurrent	$14.8B	2025-12-31	2026-02-11	10-K	26-000010
25	current liabilities	us-gaap:LiabilitiesCurrent	$7.8B	2025-12-31	2026-02-11	10-K	26-000010
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$20.5B	2025-12-31	2026-02-11	10-K	26-000010
27	operating income	us-gaap:OperatingIncomeLoss	$4.9B	2025-12-31	2026-02-11	10-K	26-000010
28	book equity	us-gaap:StockholdersEquityIncludingPortionAttributableT...	$22.4B	2025-12-31	2026-02-11	10-K	26-000010
29	liabilities	us-gaap:Liabilities	$25.4B	2025-12-31	2026-02-11	10-K	26-000010

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$481.0M	2011-12-31	2014-02-13	10-K	14-000021
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$761.0M	2025-12-31	2026-02-11	10-K	26-000010
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$4.2B	2024-12-31	2026-02-11	10-K	26-000010
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$755.0M	2024-12-31	2026-02-11	10-K	26-000010
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$3.7B	2023-12-31	2026-02-11	10-K	26-000010
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$575.0M	2023-12-31	2026-02-11	10-K	26-000010
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$2.6B	2022-12-31	2025-02-12	10-K	25-000023
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$588.0M	2022-12-31	2025-02-12	10-K	25-000023
38	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$1.6B	2025-12-31	2026-02-11	10-K	26-000010
39	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$4.5B	2025-12-31	2026-02-11	10-K	26-000010
40	income tax	us-gaap:IncomeTaxExpenseBenefit	$1.3B	2025-12-31	2026-02-11	10-K	26-000010
41	current assets	us-gaap:AssetsCurrent	$14.8B	2024-12-31	2026-02-11	10-K	26-000010
42	current liabilities	us-gaap:LiabilitiesCurrent	$7.6B	2024-12-31	2026-02-11	10-K	26-000010
43	assets	us-gaap:Assets	$39.9B	2023-12-31	2025-02-12	10-K	25-000023
44	assets	us-gaap:Assets	$36.9B	2022-12-31	2024-02-14	10-K	24-000024
45	shares outstanding	dei:EntityCommonStockSharesOutstanding	382,688,675	2026-01-31	2026-02-11	10-K	26-000010
46	shares outstanding	dei:EntityCommonStockSharesOutstanding	381,579,123	2025-01-31	2025-02-12	10-K	25-000023

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.